Summit Creek Advisors LLC reduced its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 6.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,066 shares of the biotechnology company’s stock after selling 5,720 shares during the period. Summit Creek Advisors LLC owned about 0.23% of Repligen Corporation worth $3,276,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of Repligen Corporation during the first quarter valued at about $103,000. Victory Capital Management Inc. raised its position in shares of Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares in the last quarter. Finally, 361 Capital LLC acquired a new position in shares of Repligen Corporation during the first quarter valued at about $202,000. Institutional investors and hedge funds own 96.42% of the company’s stock.
Repligen Corporation (RGEN) traded up 1.21% during midday trading on Wednesday, reaching $41.87. The company’s stock had a trading volume of 23,023 shares. The firm has a 50 day moving average of $40.59 and a 200 day moving average of $35.42. Repligen Corporation has a 52-week low of $26.16 and a 52-week high of $46.81. The firm has a market cap of $1.43 billion, a P/E ratio of 110.47 and a beta of 1.32.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.02. Repligen Corporation had a return on equity of 9.57% and a net margin of 11.93%. The firm had revenue of $30.59 million during the quarter, compared to analysts’ expectations of $29.28 million. During the same quarter last year, the firm posted $0.12 earnings per share. The company’s revenue for the quarter was up 21.9% compared to the same quarter last year. Analysts anticipate that Repligen Corporation will post $0.55 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/07/19/repligen-corporation-rgen-shares-sold-by-summit-creek-advisors-llc.html.
Several brokerages recently issued reports on RGEN. Zacks Investment Research lowered Repligen Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub lowered Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 14th. First Analysis restated an “equal weight” rating and issued a $40.00 target price on shares of Repligen Corporation in a research note on Friday, April 21st. Jefferies Group LLC restated a “hold” rating and issued a $40.00 target price (up previously from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. Finally, Janney Montgomery Scott boosted their target price on Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Repligen Corporation currently has an average rating of “Buy” and an average price target of $41.20.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.